Home

2022 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment

  1. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
  2. J Am Coll Cardiol 2017;Dec 22: [Epub ahead of print]. The following are key points to remember from this American College of Cardiology (ACC) Expert Consensus Decision Pathway for Optimization of Heart Failure (HF) Treatment, which addresses 10 pivotal issues about HF with reduced ejection fraction (HFrEF): Initiate and Switch: Initiate.
  3. Appendix 1: Author Relationships With Industry and Other Entities (Relevant)—2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members.
  4. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction Journal of the American College of Cardiology , 77 (6) : 772-810 , Online publication date: 16-Feb-2021

Expert Consensus on Optimization of Heart Failure Treatmen

2021 Update to the 2017 ACC Expert Consensus Decision

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force J Am Coll Cardiol. 2017 Feb 21. Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 7

Relationships With Industry and Other Entities (Comprehensive)—2017 ACC Expert Consensus Decision Pathway on Optimization of Heart Failure Treatment: Answers to 10 pivotal questions about heart failure with reduced ejection fraction Committee Member Employment Consultant Speakers Burea Extensive guidance for GDMT optimization after discharge is provided by the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment (13). The transition point provides clinicians with an additional opportunity to consider enhancement of GDMT for the outpatient setting (88,103,106,121,160) Expert Consensus Decision Pathways - American College of Cardiology. One of the key focus areas of the ACC is actionable knowledge, a concept that places emphasis on making clinical information easier to consume, share, integrate and update. The methodology for Expert Consensus Decision Pathway development is grounded in assembling a. The 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction will be published online in the Journal of the American College of Cardiology. The American College of Cardiology is the professional home for the entire cardiovascular care.

2021 Expert Decision Pathway for HFrEF Treatment

  1. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 77(6), 772-810
  2. Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology's 2021 update to its 2017 Expert Consensus Decision Pathway on managing.
  3. Information in this app is derived from the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment, the 2017 ACC/ AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, and the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Indications collected in the app.
  4. The American College of Cardiology (ACC) published a 2021 update to its 2017 Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure (HF) Treatment in the Journal of the American College of Cardiology.In this document, 10 issues identified as crucial for optimal management of HF with reduced ejection fraction (HFrEF) are covered, with a focus on novel therapies
  5. 2017 ACC American College of Cardiology] Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues about Heart Failure with ReducedEjection Fraction, the ACC noted that publication was meant to streamline care and improve patien

ª 2021 by The American College of Cardiology Foundation

The American College of Cardiology (ACC) has released an expert consensus decision pathway including 10 key issues regarding the treatment of heart failure (HF) with reduced ejection fraction (HFrEF). The 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment was based on the 2017 update to the HF guidelines set. DOI: 10.1016/j.jacc.2017.11.025 Corpus ID: 205595759. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways (COMPREHENSIVE)—2017 ACC EXPERT CONSENSUS DECISION PATHWAY FOR OPTIMIZATION OF HEART FAILURE TREATMENT Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Frank V. Aguirre Officia Heart failure treatment and the art of medical decision making. Finlay A Therapy for patients with heart failure and reduced ejection fraction (HFrEF) has advanced remarkably over the past three decades but the multitude of treatment options has created a dilemma for clinicians faced with choosing the appropriate sequencing of therapies. The American College of Cardiology (ACC) published a 2021 update to its 2017 Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure (HF) Treatment in the Journal of the.

HF Decision Pathway - American College of Cardiolog

2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Journal of the American College of Cardiology, 71(2), 201-230 Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021

Download 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment_ Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.pdf (4.3 MB • Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure Treatment: Answers to 10 pivotal issues about SmartPA Clinical Proposal For

The following are key points to remember from the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: 1. For patients with newly diagnosed Stage C heart failure with reduced ejection fraction (HFrEF), a beta-blocker and an angiotensin-converting enzyme inhibito The 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment lists ARNIs as the preferred agents for treatment of heart failure with reduced ejection fraction, with or without prior aldosterone antagonist or ACEI/ARB therapy. Entresto is commonly prescribed with other heart failure Source Reference: Maddox TM, et al 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with.

Expert Consensus Decision Pathways - American College of

  1. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced.
  2. Maddox T, Januzzi, J, Allen L, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772-810. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/ AHA.
  3. American College of Cardiology (Chief Scientific Advisor, NCDR); American Board of Internal Medicine (Member, Cardiovascular Board) Citation(s): Maddox TM et al. 2021 update to the 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction
  4. Maddox TM., Januzzi JL, Allen LA, et al. 2021 update to the 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction
  5. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. The American College of Cardiology task force on clinical expert consensus decision pathways
  6. Writing Committee, Maddox TM, Januzzi Jr JL, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee
  7. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol

2017 ACC expert consensus decision pathway for optimization of heart failure treatment 10 1. After a diagnosis of heart failure is made, GDMT should be initiated and therapies should be adjusted no more frequently than every 2 weeks to target doses (or maximally tolerated doses). 2 7. Yancy CW, Januzzi JL Jr, Allen LA, Butler J. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

It's just one of scores of tips in 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. The document is meant to complement the 2017 heart failure. TM Maddox et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77:772. Drugs for chronic heart failure All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

New Guidance Issued to Optimize Heart Failure Treatment - AC

This activity will review heart failure and treatment based on the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for the Optimization of Heart Failure Treatment. Faculty will review the basic mechanisms and types of heart failure. In addition, traditional medication classes will be discussed as well as new therapies in the. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;71:201-230 Maddox TM, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. J Am Coll Cardiol. 2021;77(6):772-810. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure Patient Support Tool TM Maddox et al. 2021 update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77:772

Entresto Is Top HFrEF Treatment Recommendation in Updated

Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Introduction. Heart failure (HF) is extremely prevalent and has a considerable impact on mortality and quality of life. 1 1 Yancy CW, Januzzi JL, Allen LA, Butler J, Davis LL, Fonarow GC, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology solution set oversight committee. Journal of the American College of Cardiology. Yancy, C. W., et al. (2013) An update has been issued for the 2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee

TreatHF App - American College of Cardiolog

American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 128(16), e240-e327 Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee

MADDOX TM, Januzzi JL Jr, Allen LA, Breathett K, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Jan 4. pii: S0735-1097(20)37867 Maddox TM, Januzzi JL Jr, Allen LA, et al; Writing Committee. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee Heart failure (HF) is a complex clinical syndrome characterized by abnormalities in cardiac structure and function, dynamic remodeling, and perturbations of the neurohormonal axis []; it remains one of the leading causes of hospitalization.Nearly 44% of HF patients are readmitted for cardiac and non-cardiac related conditions within 1 year of discharge and the duration of readmission ranges.

Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology task force on expert consensus decision pathways Their latest app, TreatHF combines their 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment and the 2017 ACC/AHA/HFSA Focused Update of their 2013 HF guideline into a handy point-of-care app for patients with stage C HFrEF. Providers input data on patient's current use of standard medications and enter. Publications. Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection.

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: The Role of Angiotensin Receptor-Neprilysin Inhibitor By Norman Lepor April 7, 202 This year I have tried to make a significant impact on the nationwide treatment of CHF. Working with the ACP and ACC to raise awareness of new treatment in the field that are underutilized. I have also been chosen as the ACP representative of Internal Medicine to make sure that guidelines can be understood and followed by internal medicine. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2018;71:201-230 It took 3 years for Novartis' Entresto to be mentioned in ACC/AHA guideline, but not that strong recommendation at that time. Entresto' results published in NEJM Sep 2014. 2017 ACC/AHA guideline: 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment

ACC Update on Expert Consensus Decision Pathway for

This is circling back to the guidelines we've been talking about. I want to make sure pharmacists understand the goals of guideline-directed medical therapy, or GDMT. We've already commented briefly on the 2021 update to the ACC [American College of Cardiology] Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment Access ACC guidelines and clinical policy documents as well as related resource

Yancy, C. et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 70(6):776-803. 5 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction [published online December 13, 2017] 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol

Maddox TM, Masoudi FA, Motiwala SR, Patterson JH, Walsh MN, and Wasserman A. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiolog 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction (Expert Consensus Decision Pathway Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee 4. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;Jan 1 1:[Epub ahead of print]. 5 Failure, 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction, National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in.

Amarin Corp

New HF Treatment Recommendations Issued by ACC Consultant36

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Jan 11, 2021. (来源:《国际循环》编辑部. C. W. Yancy, J. L. Januzzi, L. A. Allen et al., 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology task force on expert consensus decision pathways, Journal of the American. 1Yancy, Clyde W., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.Journal of the American College of Cardiology 71.2 (2018): 201-230

Heart failure treatment and the art of medical decision

5. Maddox TM, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;S0735- 1097(20)37867-0 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Hyperlipidemia. 2015 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 Version2021 ACC Download14 Stock∞ Total Files1 Size0.00 KB Create DateGennaio 13, 2021 Last UpdatedGennaio 13, 2021 FileActionj.2020.11.022 Download Downloa

REFERENCES - UpToDat

Yancy CW, Januzzi JL, Allen LA et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology 2017 The ACC is seeking comments on a draft of the 2020 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. This document addresses existing and emerging medical therapies, prevention and comorbidities relevant to HFrEF.

2021 Update to the 2017 ACC Expert Consensus Decision

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, et al. Alan Wasserman, MD, chair of the Department of Medicine and Eugene Meyer Professor of Medicine at SMHS, served as a senior author on the article 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction Nasrien E. Ibrahim, MD. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a . CW Yancy, JL Januzzi, LA Allen, J Butler, LL Davis, GC Fonarow,. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment_ Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.pdf 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment_ Answers to 10 Pivotal Issues About Heart Failure. Lindenfeld, F. A. Masoudi, et al., 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee., J Am Coll Cardiol, 2021 Jan 04 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee. Maddox, Thomas M., Januzzi, James L. and 15 more Journal of the American.